Entero Healthcare Solutions: Revenue Momentum Continues, Margins Improve

Entero Healthcare Solutions reported a healthy performance for the December 2025 quarter, driven by strong demand across its healthcare distribution and supply chain business. Revenue rose 26% YoY to Rs.1,707 crore, reflecting steady expansion in pharmaceutical, OTC and medical device distribution. The company’s EBITDA increased 36% YoY to Rs.67.8 crore, indicating improving operating leverage and better scale efficiencies within its integrated supply chain platform.

Net profit grew 23% YoY to Rs.33.9 crore, while EPS rose to Rs.6.35 compared with Rs.5.85 a year ago, highlighting continued profitability despite competitive pressures in the healthcare distribution segment. Sequentially, growth remained stable, suggesting sustained demand momentum rather than a one-off spike.

Incorporated in 2018, Entero Healthcare Solutions has rapidly positioned itself among India’s leading healthcare product distributors, offering both demand fulfilment and demand generation services. Its business model combines end-to-end distribution of pharmaceuticals, vaccines, nutraceuticals and surgical consumables with integrated commercial solutions such as sales, marketing and private label support. This diversified model enables the company to deepen relationships with manufacturers while expanding its presence across hospitals, pharmacies and healthcare providers.

From an outlook perspective, rising scale, strong topline growth and expanding EBITDA margins indicate improving operating strength. However, the stock trades at a premium valuation near 44x earnings, implying that future performance will depend on sustained revenue growth, margin discipline and execution within the competitive healthcare supply chain ecosystem. Investors will continue to monitor growth consistency and profitability trends as the company scales its integrated healthcare distribution platform.